Intermediate outcome and risk factor assessment of bovine vascular heterografts used as AV-fistulas for hemodialysis access

European Journal of Vascular and Endovascular Surgery

Volumn 27, Issue 6, 2004, Pages 660-665

  Widmer, M K ^a   Aregger, F ^a   Stauffer, E ^b   Savolainen, H ^a   Heller, G ^a   Hakki, H ^a   Carrel, T ^a   Schmidli, J ^a   Mohaupt, M G ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

Arteriovenous fistula; Bovine; Hemodialysis; Risk factor; Xenografts

Indexed keywords

POLITEF;

ARTERIOVENOUS FISTULA; ARTICLE; BLOOD VESSEL GRAFT; CONTROLLED STUDY; DEVICE; DIABETES MELLITUS; GRAFT PATENCY; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; POLITEF IMPLANT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; VASCULAR ACCESS; XENOGRAFT;

EID: 2442453512     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejvs.2004.01.019     Document Type: Article

References (36)

1. Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarus JM, Tilney NL. Vascular access for hemodialysis. Patency rates and results of revision. Ann Surg 1985; 202:235-239.
2. Harland RC. Placement of permanent vascular access devices: surgical considerations. Adv Ren Replace Ther 1994; 1:99-106.
3. Fan P-Y, Schwab SJ. Vascular access - concepts for the 1990s. J Am Soc Nephrol 1992; 3:1-11.
4. Windus DW. Permanent vascular access: a nephrologist's view. Am J Kidney Dis 1993; 21:457-471.
5. Munda R, First R, Alexander JW, Linnemann CC, Fidler JP, Kittur D. Polytetrafluoroethylene graft survival in hemodialysis. JAMA 1983; 249:219-222.
6. Kinnaert P, Vereertraeten P, Toussaint C, Van Geertruyden J. Nine years experience with internal arteriovenous fistulas for hemodialysis: study of some factors influencing results. Br J Surg 1977; 64:242-246.
7. Kherlakian GM, Roedersheimer LR, Arbaugh JJ, Newmark KJ, King LR. Comparison of autogenous fistula versus expanded polytetrafluoroethylene graft fistula for angioaccess in hemodialysis. Am J Surg 1986; 152:238-243.
8. Dunlop MG, Mackinlay JY, Jenkins AM. Vascular access: experience with the brachiocephalic fistula. Ann R Coll Surg Engl 1986; 68:203-206.
9. Ryan JJ, Dennis MJS. Radiocephalic fistula in vascular access. Br J Surg 1990; 77:1321-1322.
10. Albers F. Causes of hemodialysis access failure. Adv Ren Replace Ther 1994; 1:107-118.
11. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. NKF-K/DOQI clinical practice guidelines for vascular access: update 2000. Am J Kidney Dis 2001;37:S137-S181.
12. Didlake R, Curry E, Bower J. Composite dialysis access grafts. J Am Coll Surg 1994; 178:24-28.
13. Raju S. PTFE grafts for hemodialysis access. Techniques for insertion and management of complications. Ann Surg 1987; 206: 666-673.
14. Jenkins AM, Buist TA, Glover SD. Medium-term follow-up of forty autogenous vein and forty polytetrafluoroethylene (Gore-Tex) grafts for vascular access. Surgery 1980; 88:667-672.
15. May J, Harris J, Patrick W. Polytetrafluoroethylene (PTFE) grafts for haemodialysis: patency and complications compared with those of saphenous vein grafts. Aust N Z J Surg 1979; 49: 639-642.
16. Tellis VA, Kohlberg WI, Bhat DJ, Driscoll B, Veith FJ. Expanded polytetrafluoroethylene graft fistula for chronic hemodialysis. Ann Surg 1979; 189:101-105.
17. Elliott MP, Gazzaniga AB, Thomas JM, Haiduc NJ, Rosen SM. Use of expanded polytetrafluoroethylene grafts for vascular access in hemodialysis: laboratory and clinical evaluation. Am Surg 1977; 43:455-459.
18. Enzler MA, Rajmon T, Lachat M, Largiader F. Long-term function of vascular access for hemodialysis. Clin Transplant 1996; 10:511-515.
19. Doyle DL, Fry PD. Polytetrafluoroethylene and bovine grafts for vascular access in patients on long-term hemodialysis. Can J Surg 1982; 25:379-382.
20. Hylander B, Fernstrom A, Swedenborg J. Interposition graft fistulas for hemodialysis. Acta Chir Scand 1988; 154:107-110.
21. Brems J, Castaneda M, Garvin PJ. A five-year experience with the bovine heterograft for vascular access. Arch Surg 1986; 121: 941-944.
22. Hasson JE, Megerman J, Abbott WM. Suture technique and para-anastomotic compliance. J Vasc Surg 1986; 3:591-598.
23. Kovalic AJ, Beattie DK, Daies AH. Outcome of ProCol, a bovine mesenteric vein graft, in infrainguinal reconstruction. Eur J Vasc Endovasc Surg 2002; 24:533-534.
24. Bacchini G, Del Vecchio L, Andrulli S, Pontoriero G, Locatelli F. Survival of prosthetic grafts of different materials after impairment of a native arteriovenous fistula in hemodialysis patients. ASAIO J 2001; 47:30-33.
25. Beldi G, Bosshard A, Hess OM, Althaus U, Walpoth BH. Transit time flow measurement: experimental validation and comparison of three different systems. Ann Thorac Surg 2000; 70: 212-217.
26. Sidawy AN, Gray R, Besarab A, Henry M, Ascher E, Silva M, Miller A, Scher L, Trerotola S, Gregory RT, Rutherford RB, Kent KC. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 2002; 35: 603-610.
27. Wong V, Ward R, Taylor J, Selvakumar S, How TV, Bakran A. Factors associated with early failure of arteriovenous fistulae for haemodialysis access. Eur J Endovasc Surg 1996; 12:207-213.
28. Glickman MH, Stokes GK, Ross JR, Schuman ED, Sternbergh WC, Lindberg JS, Money SM, Lorber MI. Multicenter evaluation of a polyurethanurea vascular access graft as compared with the expanded polytetrafluoroethylene vascular access graft in hemodialysis applications. J Vasc Surg 2001; 34:465-473.
29. Gibson KD, Gillen DL, Caps MT, Kohler TR, Sherrard DJ, Stehman-Breen CO. Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States renal data system dialysis morbidity and mortality study. J Vasc Surg 2001; 34:694-700.
30. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2002; 40:1255-1263.
31. Griffith TF, Chua BSY, Allen AS, Klassen PS, Reddan DN, Szczech LA. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2003; 42:1260-1269.
32. Strauer BE. Beta-blocking agents in heart failure: modern concepts and overview. J Cardiovasc Pharmacol 1990; 16: S129-S132.
33. Wu L, Iwai M, Nakagami H, Li Z, Chen R, SuzuKi J, Akishita M, DE Gasparo M, Horiuchi M. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001; 104:2716-2721.
34. Mahmud A, Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens 2000; 14:541-546.
35. Taghizadeth A, Dasgupta P, Khan MS, Taylor J, Koffman G. Long-term outcomes of brachiobasilic transposition fistula for haemodialysis. Eur J Vasc Endovasc Surg 2003; 26:670-672.
36. Huber TS, Carter JW Carter RL, Seeger JM. Patency of autogenous an dpolytetrafluoroethylene upper extremity ateriovenous hemodialysis accesses: a systematic review. J Vasc Surg 2003; 38:1005-1011.